Taken together, the strength of the association between clinicopathological parameters and immunoreactive MAGE-A6 and MAGE-A11 scoring as well as MAGE-A6/MAGE-A11 co-expression can promote the potentials of these markers for diagnosis and progression of BC. Here, MAGEA6 is linked to breast cancer.